Comparative Pharmacology
Head-to-head clinical analysis: INSULIN versus MERILOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INSULIN versus MERILOG.
Insulin vs MERILOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lowers blood glucose by binding to insulin receptors on target cells, activating tyrosine kinase activity, promoting glucose uptake via GLUT4 translocation, stimulating glycogen synthesis, and inhibiting gluconeogenesis and lipolysis.
Merilog is a recombinant human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Individualized based on weight, insulin sensitivity, and metabolic needs. Type 1 diabetes: total daily dose (TDD) 0.3–1.5 units/kg/day, typically 50% basal (long-acting) and 50% prandial (rapid/short-acting). Type 2 diabetes: starting dose 0.1–0.2 units/kg/day or 10 units basal once daily, titrated based on fasting glucose. Intensive regimens use basal-bolus approach.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 5-6 minutes for regular insulin; biphasic with initial rapid phase (4-5 min) and slower phase. Clinical context: short half-life necessitates continuous infusion or multiple daily injections.
The terminal elimination half-life is approximately 18 hours, allowing for once-daily dosing in most patients. In renal impairment (CrCl <30 mL/min), half-life is prolonged to >40 hours, requiring dose adjustment.
Renal: ~60-80% (degraded in kidney); hepatic: ~20-40% (degraded in liver); only a small fraction (<1%) excreted unchanged in urine.
MERILOG is primarily excreted renally as unchanged drug (85%) and as minor metabolites (10%). Fecal excretion accounts for less than 5%.
Category A/B
Category C
Insulin
Insulin